Study Confirms PET-CT as Modern Standard for Staging Hodgkin Lymphoma

Share this content:
Researchers evaluated use of PET-CT versus CT in Hodgkin lymphoma treatment and determined that response assessment.
Researchers evaluated use of PET-CT versus CT in Hodgkin lymphoma treatment and determined that response assessment.

Positron emission tomography-computed tomography (PET-CT) is the modern standard for staging Hodgkin Lymphoma and response assessment using Deauville criteria is robust, according to a study published online ahead of print in the journal Blood.1

Because international guidelines recommend that PET-CT replace CT in Hodgkin lymphoma, researchers sought to compare PET-CT with CT for staging and measure agreement between expert readers and local readers using the Deauville criteria to adapt treatment.

For the Response Adapted Therapy in Advanced Hodgkin Lymphoma (RATHL) trial, investigators staged patients using clinical assessment, CT, and bone marrow biopsy (RATHL stage).

Patients were also staged using PET-CT, which was performed at baseline and after 2 chemotherapy cycles in a response-adapted design. PET-CT findings were then reported centrally by experts at 5 national core labs while local readers optionally scored PET-CT findings performed after 2 cycles of chemotherapy.

Results showed that RATHL stage and stage determined by PET-CT at baseline were the same in 938 (80%) patients. Researchers found that PET-CT upstaged 159 (14%) and downstaged 74 (6%) patients. PET characterization of lesions was the cause of discrepant findings for most.

The study also demonstrated that marrow biopsy upstaged 5 patients and contract-enhanced CT in bowel and/or liver or spleen upstaged 7.

The investigators determined that agreement on PET-CT findings after 2 cycles of chemotherapy amongst experts was very good and was good between experts and local readers.

The findings suggest that RATHL results can be translated into clinical practice.


  1. Barrington SF, Kirkwood AA, Franceschetto A, et al. PET-CT for staging & early response: results from 'Response Adapted Therapy in Advanced Hodgkin Lymphoma' (RATHL) (CRUK/07/033) [published online ahead of print January 8, 2016]. Blood. doi: 10.1182/blood-2015-11-679407.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs